SUTENT

Valsts: Indonēzija

Valoda: indonēziešu

Klimata pārmaiņas: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Lejuplādēt Produkta apraksts (SPC)
21-05-2021

Aktīvā sastāvdaļa:

SUNITINIB MALATE

Pieejams no:

PFIZER INDONESIA - Indonesia

SNN (starptautisko nepatentēto nosaukumu):

SUNITINIB MALATE

Deva:

25 MG

Zāļu forma:

KAPSUL

Vienības iepakojumā:

DUS, BOTOL PLASTIK @ 30 CAPSUL

Ražojis:

PFIZER ITALIA S.R.L - Italy

Autorizācija datums:

2018-01-04

Produkta apraksts

                                Generic Name
: Sunitinib Malate
Trade Name
: SUTENT
®
CDS Effective Date
: February 12, 2015
Supersedes
: October 13, 2009
Approved by BPOM
:
2020-0
061098
Page 1 of 27
PT. PFIZER INDONESIA
LOCAL PRODUCT DOCUMENT
Generic Name
: Sunitinib Malate
Trade Name
: SUTENT
®
CDS Effective Date
: February 12, 2015
Supersedes
: October 13, 2009
DESCRIPTION
SUTENT
®
, an oral multi-kinase inhibitor targeting several receptor tyrosine
kinases (RTK), is the
malate salt of sunitinib. Sunitinib malate is described chemically as
butanedioic acid, hydroxy-,
(2S)-, compound with
_N_-[2-(diethylamino)ethyl]-5-[(_Z_)-(5-fluoro-1,2-dihydro-2-oxo-_3H_-indol-3-
ylidine)methyl]-2,4-dimethyl-_1H_-pyrrole-3-carboxamide
(1:1).
The
molecular
formula
is
C
22
H
27
FN
4
O
2
.C
4
H
6
O
5
and the molecular weight is 532.6 Daltons. The chemical structure of
sunitinib malate is:
Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The
solubility of sunitinib
malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess
of 25 mg/mL. The log of
the distribution coefficient (octanol/water) at pH 7 is 5.2.
SUTENT
®
(sunitinib malate) capsules are supplied as printed hard shell
capsules containing
sunitinib malate equivalent to 12.5 mg, 25 mg or 50 mg of sunitinib
together with mannitol,
croscarmellose sodium, povidone (K-25) and magnesium stearate as
inactive ingredients.
The orange gelatin capsule shells contain titanium dioxide, and red
iron oxide. The caramel
gelatin capsule shells also contain yellow iron oxide and black iron
oxide. The printing ink
contains shellac, propylene glycol, sodium hydroxide, povidone and
titanium dioxide.
CLINICAL PHARMACOLOGY
PHARMACODYNAMIC PROPERTIES
Sunitinib malate is a small molecule that inhibits multiple RTKs, some
of which are implicated in
tumor growth, pathologic angiogenesis, and metastatic progression of
cancer. Sunitinib was
evaluated for its inhibitory activity against a variety of kinases
(>80 kinases) and was identified
as an inhibitor of platelet-derived growth factor receptors (
                                
                                Izlasiet visu dokumentu
                                
                            

Meklēt brīdinājumus, kas saistīti ar šo produktu

Skatīt dokumentu vēsturi